{"id":"W2983284890","doi":"10.1200/jco.19.02107","title":"Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1014,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Pembrolizumab; Cohort; Colorectal cancer; Tolerability; Oncology; Microsatellite instability; Irinotecan; Progression-free survival; Clinical endpoint; Oxaliplatin; Response Evaluation Criteria in Solid Tumors; Cancer; Surgery; Phases of clinical research; Adverse effect; Chemotherapy; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001721942,0.001265942,0.001209894,0.0003295442,0.0003947412,0.0007040731,0.0007303903,0.0008758027,0.003805772],"category_scores_gemma":[0.0007773715,0.000513775,0.0006159067,0.0003425473,0.000604491,0.0007691372,0.0003459552,0.002154334,0.0008366777],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008700805,"about_ca_system_score_gemma":0.001720747,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007652747,"about_ca_topic_score_gemma":0.00246127,"domain_scores_codex":[0.9996578,0.0001663437,0.00002009843,0.00005833765,0.00004439436,0.00005300025],"domain_scores_gemma":[0.9993281,0.00007218629,0.000189984,0.00005556722,0.0000549024,0.000299219],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6206783,0.1596224,0.01578213,0.001429441,0.001285406,0.0004088887,0.0003678854,0.002559752,0.1016043,0.0003984135,0.006285326,0.08957777],"study_design_scores_gemma":[0.5682686,0.4065216,0.01452614,0.00005431264,0.0002817709,0.0003708089,0.00007481747,0.001060247,0.005681141,0.0001614421,0.002972342,0.00002677658],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924729,0.001046726,0.0006546027,0.0001947649,0.00006680626,0.003531298,0.0009472016,0.00006845982,0.00101725],"genre_scores_gemma":[0.9873806,0.001245069,0.00262605,0.0006539822,0.0001441664,0.003812736,0.002057067,0.00002213898,0.002058163],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003805772,"threshold_uncertainty_score":0.01273161,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1353295079761783,"score_gpt":0.4909100416450203,"score_spread":0.355580533668842,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}